Key points from article :
Yuvan Research has developed a plasma therapy called E5 that has been shown to extend the lifespan of rats by 50%.
E5 is derived from pig plasma and is designed to be injected regularly to reverse the age of the recipient's biological systems.
Yuvan has secured early-stage funding from Longevitytech.fund to advance E5 into canine trials.
The company expects to begin the dog trial imminently and hopes to move into human trials next year.
Yuvan's CEO, Akshay Sanghavi, says that the company's work opens up "a lot of possibilities" for the treatment of aging-related diseases.
Sanghavi also says that the results of the dog trial will give the company a good indication of whether E5 will be effective in humans.
LongevityTech.fund founding partner Petr Sramek says that he is "excited to fund this advanced and promising rejuvenation approach."
Sramek adds that the Yuvan team has the "necessary qualities and experience to move this into human clinical trials."
